Methods	Six-week randomised, double-blind two-centre study.
Participants	Outpatients fulfilling DSM-III-R criteria for non-psychotic major depressive episode, lasting between 4 weeks to 2 years, single or recurrent, which was not secondary to another pre-existing psychiatric or medical condition, with a score of at least 20 on the HDRS-21. Age range: over 18 years old. Exclusion criteria: seizures, current diagnosis or history of hepatic or renal disfunction, anorexia or bulimia, other unstable medical disorder, pregnancy, lactation, childbearing potential, alcohol or substance abuse within the past year, use of psychoactive drug within 1 week of baseline, previous treatment with buproprion or fluoxetine, high suicidal risk
Interventions	Fluoxetine: 62 participants. Bupropion: 61 participants. Fluoxetine dose range: 20-80 mg/day. Bupropion dose range: 225-450 mg/day.
Outcomes	Hamilton Rating Scale for Depression (HDRS-21), CGI Severity and Improvement, Hamilton Rating Scale for Anxiety
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear